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Abstract Tumour angiogenesis is a fast growing domain in
tumour biology. Many growth factors and mechanisms have
been unravelled. For almost 30 years, the sprouting of new
vessels out of existing ones was considered as an exclusive
way of tumour vascularisation. However, over the last years
several additional mechanisms have been identified. With
the discovery of the contribution of intussusceptive angio-
genesis, recruitment of endothelial progenitor cells, vessel co-
option, vasculogenic mimicry and lymphangiogenesis to
tumour growth, anti-tumour targeting strategies will be more
complex than initially thought. This review highlights these
processes and intervention as a potential application in cancer
therapy. It is concluded that future anti-vascular therapies
might be most beneficial when based on multimodal anti-
angiogenic, anti-vasculogenic mimicry and anti-lymphangio-
genic strategies.
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1 Introduction
Tumourscangrowtoa sizeofapproximately1–2mm
3 before
their metabolic demands are restricted due to the diffusion
limit of oxygen and nutrients. In order to grow beyond this
size, the tumour switches to an angiogenic phenotype and
attracts blood vessels from the surrounding stroma. This
process is regulated by a variety of pro- and anti-angiogenic
factors, and is a prerequisite for further outgrowth of the
tumour [1]. Next to sprouting angiogenesis, the process by
which new vessels are formed from preexisting vasculature,
several other mechanisms of neovascularization have been
identified in tumours, including intussusceptive angiogene-
sis, the recruitment of endothelial progenitor cells, vessel co-
option, vasculogenic mimicry and lymphangiogenesis
(Fig. 1). Due to application for treatment of disease, these
processes gained a lot of interest over the last years. This
review summarizes the different mechanisms of tumour
vascularization, the molecular players that are involved and
their relevance in clinical practice.
2 Sprouting angiogenesis
Sprouting angiogenesis is the growth of new capillary vessels
out of preexisting ones. These blood vessels will provide
expanding tissues and organs with oxygen and nutrients, and
remove the metabolic waste. Angiogenesis takes place in
physiological situations, such as embryonic development,
wound healing and reproduction. It also plays an important
role in many pathologies, like diabetes [2], rheumatoid ar-
thritis [3], cardiovascular ischemic complications [4], and
cancer [5]. In cancer, sprouting angiogenesis is not only
important in primary tumours, it is also involved in metas-
tasis formation and further outgrowth of metastases [6].
The process of sprouting angiogenesis involves several
sequential steps. Tumour angiogenesis starts with the acti-
vation of endothelial cells by specific growth factors that
bind to its receptors. As a result, the extracellular matrix
and basement membrane, surrounding the endothelial cells,
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endothelial cells to invade into the surrounding matrix and,
subsequently, to proliferate and migrate through the matrix.
By polarization of the migrating endothelial cells a lumen is
created, and an immature blood vessel is formed [7]. The
stabilisation of the immature vessels is established by re-
cruitment of mural cells and generation of extracellular ma-
trix [8]. This process of sprouting angiogenesis is tightly
controlled by positive and negative regulators, the balance
of which determines the level of ongoing angiogenesis.
The first angiogenic growth factor, fibroblast growth
factor (bFGF), also known as FGF-2, was discovered in the
early 1980s [9]. The FGF family consists of 23 members, of
which FGF-2 and FGF-1 (aFGF) are the best known, and
four FGF tyrosine kinase receptors have been described.
bFGF stimulates all major steps in the angiogenesis cascade
and is produced by many cells, among which are macro-
phages and tumour cells. Although FGF does not have a
signal sequence that allows regular secretion, it is released in
the extracellular matrix after which angiogenesis is initiated.
bFGF is a pleiotropic mitogen forgrowth and differentiation,
known to be involved in endothelial cell proliferation, ex-
tracellular matrix degradation, endothelial cell migration and
modulation of junctional adhesion molecules. Moreover, the
intricate interaction with other growth factors can result in
many synergistic activities in endothelial cell functions [10].
In both mouse and human tumours, the role of bFGF in
tumour growth and neovascularization has been demon-
strated [11]. Neutralizing antibodies and siRNA techniques
have been described to inhibit tumour growth and neo-
vascularization in mouse models [12, 13].
Vascular endothelial cellgrowthfactor(VEGF)or vascular
permeability factor, is another important player in the
stimulation of angiogenesis. VEGF is a general activator of
endothelialcellproliferationandmobility.Itisthemostpotent
factor that induces vasodilatation of the existing vessels and
increases permeability of the vessel wall [14]. Moreover, it
increases the expression of matrix metalloproteinases and
plasminogen activators for the degradation of the extracel-
lular matrix and subsequently endothelial cell migration [15].
The VEGF family of growth factors consists of six members
(VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and
placental growth factor) that interact differentially with three
cell surface receptor tyrosine kinases, the VEGFRs, or a
second class of non-signalling co-receptors, the neuropilins.
To date, the VEFG-A/VEGFR2 interaction appears to play a
major role in sprouting angiogenesis [7]. In tumours, higher
levels of VEGF are detected and many tumour cell lines
were found to be inhibited in vivo by antibody targeting
methods or the use of small-molecule inhibitors of VEGF or
VEGFR2 [14].
Placental growth factor (PLGF), a member of the VEGF
family that only binds VEGFR1, is also a mediator of the
angiogenic switch, though its role was underestimated.
However, activated endothelial cells are known to produce
large amount of PLGF and thereby regulating the VEGF-
mediated angiogenic switch. Moreover, other cell types like
smooth muscle cells, inflammatory cells and tumour cells
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Fig. 1 Different mechanisms of
tumour vascularisation. This di-
agram represents the six differ-
ent types of vascularisation
observed in solid tumours, in-
cluding sprouting angiogenesis,
intussusceptive angiogenesis,
recruitment of endothelial pro-
genitor cells, vessel co-option,
vasculogenic mimicry and
lymphangiogenesis. The main
key players involved in these
processes, if known, are indi-
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tantly, PLGF seems to play a role in vascular development
but does not affect the functionality of physiological vessel
formation during development and reproduction [17].
The angiopoietin family, another important growth factor
family in angiogenesis, includes three members (in humans),
angiopoietin-1, angiopoietin-2 and angiopoietin-4, that all
bind to the endothelial tyrosine kinase receptor Tie-2. The
most remarkable characteristic of this family is the opposing
effect of the different ligands binding to the same receptor.
Angiopoietin-1 activates the Tie-2 signalling while angio-
poietin-2 inhibits this activation. Angiopoietin-1 is involved
in endothelial cell migration, adhesion and the recruitment of
pericytes and smooth muscle cells, while angiopoietin-2 is
vessel destabilizer [18, 19].
Besides the above described angiogenic factors, tumour
cells can produce other factors like transforming growth
factor-β, which stabilizes newly formed vessels and sup-
presses the immune system [20], platelet-derived growth fac-
tor, which is a chemoattractant for pericytes [21], epidermal
growth factor, which promotes tumourangiogenesis by
upregulating VEGF [22] and interleukin 8 that specifically
enhances endothelial cell migration [23].
Recent studies have shown similarities in the molecular
regulation of guidance of neural and endothelial cells. Spe-
cialized endothelial cells, resembling axonal growth cones,
are located at the tips of growing capillaries. These tip cells
extend and retract their filopodia continuously to explore the
environment and to define the direction in which a new
vascular sprout grows [24]. Both axon growth cones and
endothelial tip cells seem to use a repertoire of molecular
ligand/receptor signalling systems including the family of
Ephrins, Semaphorins, Slits, Netrins and Notchs. Most of
these molecules seem to play a role in tumour angiogenesis.
The injection of soluble Ephrin receptors was found to
successfully inhibit tumour angiogenesis in an animal model
[25]. Also semaphorins are hypothesised to have tumour
suppressor characteristics since overexpression has been
shown to inhibit metastasis in melanomas and highly metas-
tatic melanoma cells showed a downregulation of expression
[26]. On the other hand, Sema4D, a pro-angiogenic factor
released by tumour cells, promoted invasion and metastasis
[27]. Likewise, the Slit/Robo signalling seems to promote
tumour angiogenesis. Neutralization of Robo1 reduced the
microvessel density and the tumour mass of human malig-
nant melanoma in vivo. Moreover, there is evidence of
molecular crosstalk between cancer cells and endothelial
cells [28]. Furthermore, the implication of netrins and their
receptors has been studied. The positive signalling pathway
of netrins that normally activates apoptosis, seems to be
inactivated in tumours. Binding of netrin-1 to its receptors
inhibits the tumour suppressor activity of p53 [29]. There is
increasing evidence that Notch signalling is also involved in
tumour angiogenesis, although it seems to have both onco-
genic and tumour suppressive roles [30]. It is obvious that
the specific role (stimulatory and inhibitory effects) of these
molecules in angiogenesis needs further research.
Sprouting angiogenesis can also be negatively regulated.
Thrombospondin-1 was among the first naturally occurring
angiostatic agent to be discovered [31]. Later on, more endo-
genous molecules with angiostatic activity were described.
Among these were the 16 kD fragment of prolactin [32],
platelet factor-4 and interferon-α [33] and interferon-γ
inducible protein-10 [34]. Other members of this class of
endogenously produced anti-angiogenic proteins are angio-
statin [35], endostatin [36], bactericidal/permeability increas-
ing protein [37], tumstatin [38]. It is interesting to note that
many of these molecules are proteolytic fragments of endo-
genous macromolecules. Although for several of the
currently described angiogenesis inhibitors receptors have
been described, detailed mechanisms of action, in most
cases, are still obscure [39].
Next to anti-angiogenesis approaches with endogenous
inhibitors, several blocking strategies of the above de-
scribed angiogenic factors have been reported. Strategies
that block the VEGF-A/VEGFR2 signalling are the most
abundant ones in the clinical field of anti-angiogenic the-
rapy. A lot of attention is focussed on the approval of the
first anti-angiogenic agent, Avastin, by the Food and Drug
Administration [40, 41]. Avastin in combination with che-
motherapy demonstrated a survival benefit in patients with
metastatic colorectal cancer of several months [42]. Al-
though a beneficial clinical effect is present, in some pa-
tients gastrointestinal perforations, thromboembolic events
and impaired wound healing was observed [42]. Moreover,
recent warnings about possible visual and neurological
long-term problems in patients administrated with Avastin,
will probably delay the FDA approval for more applications
[43, 44]. Besides Avastin, several other VEGF inhibitors
are being clinically implicated. The most advanced receptor
tyrosine kinase inhibitors that target VEGF receptors are
SU11428, BAY 43-9006 [41].
Next to the reported side effects of anti-angiogenic in-
hibitors, also induction of resistance against these agents
must be acknowledged. There is emerging evidence that
VEGF-A may be replaced by other angiogenic pathways
and other members of the VEFG family [45]. Other mecha-
nisms that can participate in resistance are the selection of
more hypoxia resistant cells that are less dependent on an-
giogenesis [46] and the normalization of tumour vessel that
become less responsive to anti-angiogenic therapy [47].
Moreover, the hypothesis that endothelial cells are more
genetically stable than tumour cells (and thus less sensible
to develop resistance) is now questioned, especially after
several reports on genetic abnormalities in endothelial cells
of tumour vessels [48, 49].
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volved in sprouting angiogenesis have been identified, it is
clear that the inhibition of this process is very complex.
Clinical trials in patients with less advanced stages of can-
cer, and the long-term effects of approved compounds will
guide us to the use of angiostasis in the clinical manage-
ment of cancer. However, already now, it seems very likely
that efficient cancer therapy will be composed of combina-
tion of chemotherapy and anti-angiogenic strategies that
target multiple angiogenic pathways.
3 Intussusceptive angiogenesis
A variant of angiogenesis, different from sprouting, is in-
tussusceptive angiogenenesis. This process was first ob-
served in postnatal remodelling of capillaries in the lung
[50]. In the third week of rat life and during the first 2 years
in humans, the volume of the lungs increases by more than
20 times. In this developmental process, a new concept of
vessel formation was found where preexisting vessels split
in two new vessels by the formation of transvascular tissue
pillar into the lumen of the vessel.
Intussusceptive microvascular growth is a fast process
that can take place within hours or even minutes, because it
does not need proliferation of endothelial cells. In this pro-
cess endothelial cells are remodelled by increasing in vol-
ume and becoming thinner. Intussusception is believed to
take place after vasculogenesis or angiogenesis to expand
the capillary plexus, in a short time and with a little amount
of energy. Transmission electron microscopy revealed four
consecutive steps [51]. First, the endothelial cells of op-
posite walls make a “kissing contact”, by which a trans-
luminal bridge is formed. Secondly, a reorganisation of the
interendothelial junctions and perforation of the endothelial
bilayer is executed. In the third phase, the interstitial pillar
is formed and pericytes and myofibroblasts invade and
cover the newly formed interstitial wall. In this stage, trans-
luminar pillars have a diameter of ≤2.5 μm. It is hypo-
thesised that pericytes, with their contractile characteristics,
are the main stimulator in this phase. During the final
phase, the pillars grow in diameter and the endothelial cells
retract and two separated vessels are formed. Pillar for-
mation and remodelling is not only observed in capillary
plexuses but also within smaller arteries and veins [52].
In 1993, the first in vivo intussusceptive microvascular
growth was demonstrated by video microscopy in a chick
chorioallantoic membrane [53]. This process has now been
detected in various organs, tissue repair processes and also
in tumour angiogenesis. Tissue pillars were detected in a
colon carcinoma xenograft model. At the growing edge
both sprouting and intussusceptive angiogenesis were ob-
served, in the stabilised regions mostly intussusception was
detected [54]. Patan et al. [54] also hypothesised that
intravascular blood flow patterns or changes in shear stress
are parameters that regulate pillar formation. In mammary
tumours of c-neu transgenic mice, smaller tumour regions
exhibited numerous sprouts, while in larger tumours re-
gions frequently pillar- and mesh formations were ob-
served. Very often, these two forms of angiogenesis were
seen in parallel in the same nodule. There are some indi-
cations that absence of VEGF is important in the induction
of intussusceptive angiogenesis in fast growing tumours
[55]. Also in human melanomas a high number of intra-
luminal tissue folds and a correlation between VEGF and
intussusceptive angiogenesis has been observed [56].
Although the mechanism of intussusception is not fully
understood, there are several key players that could in-
fluence pillar formation. Alteration in blood flow dynamics
in arterial branches could stimulate this process, as ob-
served in the chick chorioallantoic membranes [52]. Fur-
thermore, changes in shear stress on the endothelial cells,
and in wall stress on the pericytes, can activate a bio-
chemical cascade which might result in cytoskeletal re-
arrangements and adaptations of gap junction complexes
[51]. The changes in shear stress can be sensed by the
endothelial cells and transduced by molecules such as CD31,
resulting in increased expression of angiogenic factors,
adhesion molecules and endothelial nitric oxide synthase
[52]. Although many cells appear to play a role in the pro-
cess of intussusception, such as the endothelial cells, peri-
cytes, macrophages and blood cells, it is now widely thought
that it is mainly mediated by endothelial cell-endothelial cell
and endothelial cell-pericyte interactions. Factors, that are
known to be involved in these interactions in sprouting
angiogenesis, such as the angiopoietins and their Tie-
receptors, platelet derived growth factor-B, monocyte che-
motactic protein-1, ephrins and EphB-receptors, are candi-
dates for the mediation of intussusceptive angiogenesis [51].
Injection of platelet derived growth factor-B in a developing
chick chorioallantoic membrane stimulated the process of
intussusception [57]. Transgenic mice that overexpress
VEGF-A and angiopoietin-1 developed blood vessels that
showed small holes in the capillary plexus, representing
transluminal pillar formation [58].
It can be hypothesized that inhibition of sprouting angio-
genesis may stimulate the process of intussusceptive angio-
genesis. Therefore, it could be a means of drug-resistance
against anti-angiogenic agents. The fact that intussusception
only involves migration of endothelial cells and vascular
remodelling but not cell proliferation, makes it unlikely that
anti-proliferative agents will be able to prevent intussus-
ception. In order to develop effective anti-angiogenesis
strategies, novel compounds should involve anti-migration
characteristics as well.
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Until 1997, the growth of new blood vessels in adults was
considered to exclusively occur through the mechanism of
sprouting and intussusceptive angiogenesis. This paradigm
of vascular development changed after the discovery of
CD34-enriched subpopulation of mononuclear blood cells
[59]. These cells were able to adapt ex vivo to an adherent
cell type with an endothelial phenotype. They were named
endothelial progenitor cells or angioblasts. It is now gen-
erally accepted that new vessels can also grow through the
recruitment of endothelial progenitor cells (EPCs) that are
circulating in the blood. EPCs express several endothelial
specific markers like CD34, CD31, VEGFR2, Tie-2 [59]
and CD14 [60]. The first in vivo observations of incorpo-
ration of EPCs in blood vessels were evident from different
mouse and rabbit bone marrow transplantation models. In
these models, with heterologous, homologous and autolo-
gous transplantation/incorporation of CD34+, CD133+,
VEGFR2+ mononuclear blood cells, EPCs incorporated
exclusively in blood vessels of neovascularised ischemic
limbs [59]. Moreover, transplantation of endothelial pro-
genitor cells improved limb perfusion, increased capillary
density and reduced the risk of limb loss [60]. In another
setting, Lin et al. [61] showed incorporation of cultured
mononuclear cells in blood vessels after a sex-mismatched
bone marrow transplantation.
The mobilization and recruitment of EPCs is promot-
ed by several growth factors, chemokines and cytokines,
which are produced during processes such as physiological
stress (tissue ischemia), physical exercise and tumour
growth. Mobilization of endothelial progenitor cells starts
with the activation of matrix metalloproteinase-9, which in
turn promotes the transformation of membrane-bound Kit
ligand to a soluble form. Subsequently, early c-kit positive
progenitor cells will detach from the bone marrow niche,
move to the vascular zone of the bone marrow and will
be released in the circulation [62]. Angiogenic factors
l i k eP L G Fa n dV E G F ,w h i c hb i n dt ot h eh i g h l ye x p r e s s e d
VEGFR2 on EPCs, stimulate the release of EPCs form
t h eb o n em a r r o w[ 63, 64]. Other factors that can elevate
the release of EPCs are stromal cell-derived factor-1,
which binds to CXCR-4 on the EPCs, and angiopoetin-1
[65]. A key player in the activation of matrix metal-
loproteinase-9 by VEGF and stromal cell-derived factor-1,
was found to be endothelial nitric oxide synthase [66].
Furthermore, factors like granulocyte colony-stimulating
factor and granulocyte-macrophage colony-stimulating
factor have identified as bone marrow stem cell mobilizing
factors [67].
The recruitment and integration of EPCs implicates a
complex multistep process, including chemoattraction, ac-
tive arrest and homing within angiogenic vasculature, trans-
migration to the interstitial space, incorporation into the
microvasculature and differentiation into mature endothelial
cells. P-selectin, E-selectin and integrins are considered to
be important in the adhesion of EPCs to the vessel wall
and in transendothelial migration [68, 69]. A recent paper
demonstrated a functional role of high-mobility group box
1 (HMGB1) in the homing of EPCs. The HMGB1-induced
migration of EPCs could be inhibited by antibodies against
β1 and β2 integrins [70]. During diapedesis CD31 and
CD99 mediate the passage of EPCs [71, 72]. The differen-
tiation of EPCs to mature endothelial cells is mainly medi-
ated by VEGF [59, 73]. After differentiation to a mature
endothelial cell, EPCs lose their progenitor properties and
start to express endothelial markers like VE-cadherin, von
Willebrand facor and endothelial nitric oxide synthase [61].
EPCs also home in at the site of neovascularization in
tumours. Asahara et al. [74] were the first to report the
incorporation of β-galactosidase labelled progenitor cells in
both tumour stroma and the endothelial layer of tumour
blood vessels. These findings led to the hypothesis that
EPCs not only incorporate into the vascular endothelium
but also can secrete pro-angiogenic factors in the perivas-
cular sites in the tumour stroma. Later on, the family of Id
(inhibitor of DNA binding) proteins was shown to play an
important role during incorporation of EPCs in tumour
endothelium. Id 1/3 double-mutant mouse embryos had
vascular malformations in the brain, leading to fatal
haemorrhage [75]. Moreover, adult Id1
+/−/Id3
−/− mice could
not support metastasis and growth of three different tumour
cell lines, while transplantation of bone marrow cells of
wild-type mice could restore this effect [76]. The contribu-
tion of EPCs to the actual vessel growth, however, is
variable. In tumours there are reports of EPCs being the
leading process in tumour angiogenesis, while others de-
scribed a minimal contribution to tumour vasculature [76–
82]. In studies with cancer patients similar mixed results
were found. In breast carcinoma patients, a higher level of
EPCs was detected in the peripheral blood and was sug-
gested as a prognostic marker in tumour patients [83]. In
contrast, the number of EPCs in the blood was not found to
be increase in a patient group of 52 gastric cancer and 19
breast cancer patients in comparison to control patients
[84]. These contradictory results on the contribution EPCs
could be due to difference in methodology.
Although most clinical applications of EPCs are in the
field of ischemic tissue recovery, inhibition of EPC mobi-
lization from bone marrow has tremendous potential in
cancer treatment. Some studies have demonstrated an
impaired role of EPCs in angiogenesis after specific
interventions. In Id mutant knock out mice with xenograft
tumours impaired tumour growth was observed [75]. In a
study by Capillo et al. [85], endostatin was described as a
potent inhibitor of mobilization and clonogenic potential of
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VEGFR1 demonstrated an effective inhibition of mobiliza-
tion and incorporation of EPCs in tumour vasculature [76].
Another clinical application of EPCs is their use as a
marker for validation of effectiveness of anti-angiogenic
therapy. In 8 different mouse strains there was a striking
correlation between bFGF- of VEGF-induced angiogenesis
and the level of EPCs [86]. Alternatively, EPCs might be
another source of tumour-homing cells to deliver toxins to
the tumour. CD34+ cells that where transfected with a
thymidine kinase gene showed a co-localisation with tu-
mour vasculature. As expected, the recruitment of these
transfected EPCs inhibited tumour growth [87]. However,
the success of the use of EPCs in cancer treatment depends
on the isolation of the proper CD34+, VEGFR2+ haema-
topoietic cells from the bone marrow or out of circulation.
There is still controversy on the exact characterisation of
EPCs and possible contamination of the EPC population
with circulating endothelial cells [88]. Moreover, the exact
molecular pathways that are involved in the mobilization
and homing of EPCs to tumours, still have to be elucidated.
Improvement of purification of these progenitor cells and
study of their long-term effect to generate endothelial
cells in vivo will clarify this embryonic field of cancer
research. Nonetheless, it is obvious that the impact of
EPCs in tumour vascularization cannot be neglected and
the development of targeting strategies to prevent them
from incorporating in regions of neovascularization in the
tumour is a new challenge.
5 Vessel co-option
As stated above, it is generally accepted that growth of
tumours and metastases start as an avascular mass and
must induce the development of new vessels to grow be-
yond a few millimeters in size. However, it has been sug-
gested that many tumours can grow in an avascular stage,
mainly in well-vascularized tissue like brain and lung [89–
91]. Tumour cells can grow along existing vessels without
evoking an angiogenic response. This process was defined
as vessel co-option.
The first evidence of this process was found during
experiments for the search for the molecular players, like
angiopoietins, that are involved in early angiogenic events
[92]. After 1 or 2 week(s) after implantation of C6 glioma
cells in a rat brain, the small tumours were already well
vascularized with vessels that had characteristics of normal
brain vessels. Moreover, no angiogenic response was
observed. After 4 weeks, blood vessels had undergone a
dramatic regression without any compensatory angiogenic
response. In the center of the tumour, tumour cells were
organised around the few functional vessels and massive
tumour cell death was detected. In the tumour periphery, in
contrast, a robust angiogenic response was observed. These
data showed that most malignancies and metastases orig-
inate as an avascular mass, co-opt with host vessels and
are rescued. It can be hypothesized that the regression of
the initial co-opted vessels is a host defence mechanism.
Unfortunately these remaining tumour cells are rescued in a
later stage, by robust angiogenesis at the outer rim of the
tumour.
The finding that vessel regression was associated with the
regression of endothelial cells, due to detachment of pericytes
and smooth muscle cells, raised the hypothesis that angio-
poietins could be involved in this process. Holasch et al.
discoveredhighangiopoietin-2expressioninco-optedvessels
of 2 weeks old tumours and in late-stage tumours with a
necrotic core. The expression of VEGF, however, was rather
low in early-stage tumours and increased later on. The ex-
pression of angiopoietin-1 did not change throughout tumour
development. Angiopoietin-2 seems to be the key regulator in
the regression of initially co-opted tumour vessels. While the
expression of angiopoietin-2 in the absence of VEGF faci-
litated vessel regression, the co-expression of angiopoietin-2
and VEGF, induced the activity of VEGF and subsequently
vessel sprouting. This operation between the two angiogenic
factors is similarly present in developmental angiogenesis
[19]. The same expression levels of angiopoietin-2 and
angiopoietin-1 were found in human glioblastomas and not
in normal brain vasculature [92]. Vessel co-option has now
been observed in different tumour types like murine Lewis
lung carcinoma, murine ovarian cancer, human melanoma
and human Kaposi sarcoma [92–95]. The role of VEGF in
vessel co-option suggests that anti-VEGF therapies may be
considered not only for blocking angiogenesis but also to
inhibit maturation of vessels in the process of vessel co-
option. However, the systemic anti-angiogenesis treatment of
a glioblastoma with an anti-VEGFR2 antibody was able to
reduce tumour angiogenesis but led to an increased co-
option of host vessels in the brain [96]. Thus, more potent
VEGF-inhibitors are needed to prevent both angiogenesis
and vessel co-option. Maybe targeting of VEGF, together
with angiopoietins, could overcome the growth of tumours
along existing vessels.
6 Vasculogenic mimicry
In 1999, the term “vasculogenic mimicry” was introduced
to describe the masquerade of tumour cells as endothelial
cells. This process of cell plasticity occurs mainly in
aggressive tumours in which tumour cells dedifferentiate
to an endothelial phenotype and make tube-like structures.
This mechanism provides tumour cells with a secondary
circulation system of vasculogenic structures lined by tu-
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nomenon was described for the first time in melanomas.
Tissue sections of uveal and cutaneous melanomas and
their respective liver metastases revealed patterned net-
works of interconnected loops of extracellular matrix, as
identified by periodic acid-Shiff’s reagent (PAS) staining.
Importantly, the presence of PAS patterns was associated
with worse patient outcome [98]. Further research sug-
gested that these PAS positive networks might be in close
connection with regular blood vessels and can be detected
with markers for endothelial cells. Furthermore, endothelial
cells could not be identified, strongly suggesting that these
vessel-like structures are lined by tumour cells. The same
patterned networks could be obtained in vitro in collagen
and matrigel three-dimensional cultures with aggressive
melanoma cell lines but not with poorly invasive melanoma
cell lines [97].
Microarray analysis comparing highly invasive and
poorly invasive melanoma cells from the same patient in-
dicated a genetic reversion of aggressive melanoma cells to
an undifferentiated embryonic-like phenotype [99]. Endo-
thelium associated genes such as VE-cadherin, Ephrin A2
and tissue factor pathway inhibitors, CD34, tyrosine kinase
receptor 1, neuropilin 1, E-selectin and endoglin (CD105)
had a more than 2-fold increased expression in vasculo-
genic mimicry positive cells. Also several matrix related
components had an increased expression such as laminin
5γ2, fibronectin, collagen IV α2, collagen I. Genes related
to a melanocytic phenotype, like Melan-A, microphthalmia-
associated transcription factor (MTIF) and tyrosinase, were
more than 20-fold downregulated.
The exact mechanism underlying vasculogenic mimicry
still needs to be unravelled. Several molecules have been
identified to have a functional role. For example, PI3 kinase
(PI3K) was proposed as the key player in activating the
transmembrane metalloproteinase MT1MMP [99]. This
protease activates matrix metalloproteinase-2 that cleaves
laminin 5γ2 into pro-migratory fragments used for tumour
cell migration in vasculogenic mimicry [100]. There is also
a role for VE-cadherin and Ephrin A2 since downregulation
of these genes in melanoma cells resulted in an abrogation
of their ability to form vasculogenic-like structures [101].
Both molecules are found to co-localize and VE-cadherin
can regulate the expression of EphA2 through its receptor
ephrin-A1. So far, several other molecules, mostly found by
means of siRNA techniques or anti-body blocking techni-
ques, have been described to play a role in vasculogenic
mimicry. Tissue factor pathway inhibitor 2 (TFPI-2) was
discovered to be necessary for vasculogenic network for-
mation and is involved in the activation MMP-2. Further-
more, several recent papers reported on different molecules
like focal adhesion kinase, cyclooxygenase-2, bone mor-
phogenetic protein-4, insuline-like growth factor binding
protein 3 and Nodal and their role in promoting an ag-
gressive melanoma phenotype [102–106].
Next to the above described mediators, genetic charac-
terisation of cell plasticity of tumour cells revealed several
molecules that are related to extracellular matrix like
fibronectin, collagen IV α2, collagen I. The importance of
the extracellular matrix, as a component of the microenvi-
ronment, in vasculogenic mimicry was demonstrated by
Seftor et al. [107]. Normal epidermal melanocytes, exposed
for 4 days to an extracellular matrix conditioned by metas-
tatic cutaneous melanoma, were reprogrammed to a geno-
type with specific genes that were associated with the
ability to form vasculogenic-like networks. Importantly,
these changes in gene expression were only transient, be-
cause gene analysis after 7 to 21 days revealed a normal
melanocyte phenotype. Recent findings suggested that an-
other microenviromental component, oxygen, may be es-
sential in melanocyte transformation. Low levels of oxygen
or hypoxia, are known to promote melanoma cell invasion,
metastasis and transformation [108, 109]. Moreover, hyp-
oxia induces vasculogenic mimicry tube formation in vitro
in a matrigel assay [110, 111]. In another paper, a B16
melanoma ischemic limb mouse model was used to mimic
an hypoxic environment. Initially a decreased tumour growth
was observed while later on there was no difference in size
with the control tumours. However, the amount of vasculo-
genic mimicry channels and the gene expression of HIF-1α,
MMP-2, MMP-9 and VEGF was increased [112]. The role
of several known tumour growth factors has also been
studied, though with disappointing results. Several growth
factors, such as basic fibroblast growth factor, vascular en-
dothelial growth factor, transforming Growth Factor-β,
platelet derived growth factor and tumour necrosis factor-α
were found not to be able to induce formation of vascular
networks when added to the poorly invasive melanoma cell
lines [97]. This indicates that angiogenesis and vasculogenic
mimicry, in contrast to the previous described tumour vas-
cularization types, are not sharing the same signalling
pathways. Moreover, anti-angiogenic targeting strategies do
not inhibit the process of vasculogenic mimicry [111]a n d
could even induce the formation of vasculogenic mimicry
vessels as an escape mechanism of the tumour to keep on
growing.
Although the functionality and the contribution of
vasculogenic-like channels to circulation was criticised at
first, several papers evidenced its functional role in tumour
circulation. The contribution of vasculogenic mimicry pat-
terns was first proven in vitro. Looping patterns, that were
formed in vitro by highly aggressive melanoma cell lines,
distributed fluid after microinjection [97]. Several groups
tried to prove the fluid-conducting characteristic of vascu-
logenic mimicry channels in vivo. Clarijs et al. co-localised
an intravenous injected tracer with both blood vessels and
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Shirakawa et al. [114] reported on blood flow in areas of
vasculogenic mimicry in a breast carcinoma model using
MRI techniques. Another approach was used by Ruf et al.
[115], where Doppler ultrasonography was used to show
blood flow in these vasculogenic-like channels. The first
in vivo demonstration of blood circulation in vasculogenic
mimicry tubes in humans was observed with laser scanning
confocal angiography in patients with a choroidal melanoma
[116]. Up to now, tumour cell plasticity has been described
in uveal [98], cutaneous [117] and oral [118] melanoma,
breast carcinoma [114], prostatic carcinoma [119], ovarian
carcinoma [120], hepatocellular carcinoma [121], bladder
carcinoma [122], rhabdomyosarcoma and mesothelial sarco-
ma [123], osteosarcoma [124], astrocytoma [125], pheochro-
mocytoma [126] and Ewing sarcoma [111].
The recent findings on the ‘plastic’ endothelial-like phe-
notype of melanoma and other tumour cells confused the
field of cancer biology even more. The idea that these
structures could form a functional secondary vascular net-
work that provides the tumour of blood, independent from
angiogenic growth factors, makes tumour growth inhibition
even more complex. A variety of genes has been investi-
gated concerning their role in tubular network formation of
tumour cells. An option for therapy is the use of mono-
clonal antibodies to these molecules for drug targeting.
However, the therapeutic functionality and the choice of the
best targets still need to be elucidated. It is evident now that
the microenvironment plays an important role in tumour
progression and therefore is a novel target for therapy. An
initial study to target MMPs was performed. The adminis-
tration of a chemically modified tetracycline, COL-3, to
aggressive melanoma cells in three-dimensional culture,
inhibited MMP-2, MMP-9, MT1-MMP and VE-cadherin
expression. Next to that, the cleavage of laminin 5 was
inhibited and decreased vascular network formation was
observed [127]. However, caution is warranted since ad-
ministration of modified tetracyclines have reported serious
side effects [128, 129]. In another paper, the addition of
anti-angiogenic compounds TNP470, anginex and endo-
statin could not block the formation of networks [130].
Until now, only very limited data on targeting vasculogenic
mimicry is available. Clearly, more investigation, on es-
sential regulatory pathways of plastic tumour cells that do
not overlap normal biological processes, is needed to de-
velop new promising therapeutic approaches.
7 Lymphangiogenesis
Lymphatic vessels are also part of the vascular circulatory
system. The lymphatic system is a network of capillaries,
collecting vessels and ducts that drains most of the organs.
In contrast to the blood vascular network, the lymphatic
network is an open ended, one way transport system, with-
out a driving force, that drains extravasated fluid, collects
lymphocytes and returns it to circulation [131]. Over the
last years there is accumulating evidence for a role of the
lymphatic system in tumour progression. Metastasis of
malignant tumours to regional lymph nodes is one of the
early signs of cancer spread in patients. In certain cancer
types, such as breast cancer, lymphatic metastasis is one of
the predominant routes of cancer spread [132]. From the
lymphatic system, cancer cells can spread to other organs
and tissues.
The lymphatic system has not received as much sci-
entific attention as the blood vascular system, maybe due to
a lack of specific markers and to the lack of knowledge
about the molecular regulation of its development and
function. The possibility and optimisation to isolate and
culture lymphatic endothelial cells, however, has led to the
identification of several markers that are specific for the
lymphatic vasculature [133]. Vascular endothelial growth
factor receptor-3 (VEGFR-3) was the first lymphatic mark-
er that was identified [134]. Later on specific markers such
as lymphatic vascular endothelial hyaluronan receptor-1
(LYVE-1) [135], podoplanin [136] and transcription factor
Prox1 [137] were identified.
Similar to blood endothelial cells, lymphatic endothelial
cells are quiescent under physiological conditions. Exper-
imental evidence for a ‘lymphangiogenic switch’ is still
lacking. Nonetheless, it seems likely that the formation of
new lymphatic vessels is triggered in a similar way as
angiogenesis of blood vessels. Already now, a range of
lymphangiogenic factors/receptors that are produced by tu-
mour cells and inflammatory cells have been identified.
After the identification of the lymphatic specific marker
VEGFR-3, both VEGF-C and VEGF-D were cloned as
unique ligands for this receptor [138]. In the development
of the lymphatic system, the role of VEGF-D is dispensable
[139], whereas VEGF-C null mouse embryos completely
lack a lymphatic vasculature and die prenatally [140]. In
vitro, VEGF-C stimulated proliferation, migration and sur-
vival of lymphatic endothelial cells [141]. To demonstrate
the VEGF-C/VEGF-D/VEGFR-3 signalling pathway in tu-
mour lymphangiogenesis, tumour cells expressing VEGF-C
and -D were used in a mouse tumour model. Both the
expression of VEGF-C and -D increased intratumoural
lymphangiogenesis and metastasis. In addition, a blocking
VEGF-D antibody could inhibit this lymphatic spread [142,
143]. Furthermore, there are indications that there is a cross
talk between blood vessel angiogenesis and lymphangio-
genesis. Angiogenic mediators are identified to play a role
in lymphangiogenesis but their role is mostly studied in
physiological situations. The VEGF-A/VEGFR-2 signalling
pathway stimulates lymphangiogenesis. However, the new
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and structurally abnormal [144]. The group of Chang et al.
[145] demonstrated that bFGF could induce both blood
vessel angiogenesis and lymphangiogenesis and even lymph-
angiogenesis alone depending on the dose of bFGF that was
administrated on mouse cornea. In the same mouse cornea
model, PDGF-BB was found to be the most potent of the
PDGF family in stimulating lymphangiogenesis [146].
Above that, PDGFs are often found to be highly expressed
in tumours that have increased incidence of lymphatic me-
tastasis [147]. The first evidence of a role of angiopoietin-2
in lymphangiogenesis was suggested by the angiopoietin-2-
null mice that displayed disorganized and hypoplastic
lymphatic capillaries [148]. Importantly, the lymphatic but
not the blood vessel phenotype could be rescued by genetic
transfer of angiopoietin-1. In addition, Morisada et al. [149]
were able to demonstrate the stimulation of both in vitro
growth of lymphatic endothelial cells and lymphangiogen-
esis in the mouse cornea by angiopoietin-1. Similarly to
angiopoietin-2-null mice, NRP-2 mutants showed absence
or severe reduction of small lymphatic vessels and ca-
pillaries [150]. Also an in vitro and in vivo stimulatory role
of hepatocyte growth factor [151] and insulin-like growth
factor-1 and -2 [152] on the lymphatic vessel formation was
observed.
Now that specific markers are available and some insight
into the biology of lymphangiogenesis is available, it
becomes evident that lymphangiogenesis is an important
parameter in the process of tumour growth [153]. Neverthe-
less, there is still an ongoing debate on the role of lymph-
angiogenesis in tumour progression. It was previously
thought that lymphatic metastasis occurred by preexisting
lymphatic vessels that are present at the outer rim of the
tumour. However, other papers report on the presence of
peritumoural and/or intratumoural lymphatics, not only in
mouse studies but also in human tumours. Nevertheless,
intratumoural lymphatics are rare and their functionality
and role in tumour metastasis is still discussed [154, 155].
There are also reports that lymph angiogenesis parameters
such as lymph vessel density, lymph angiogenic growth
factors [156], or the presence of tumour cells within lymph
vessels or lymph nodes are valuable prognostic markers
[157–161].
The high incidence of metastatic lymphatic spread and the
knowledge of several lymphangiogenic markers urged
researchers to investigate the inhibition of lymphangio-
genesis as a strategy of tumour treatment. Stacker et al.
[143] reported the reduction of lymphatic spread by block-
ing VEGF-D with a monoclonal antibody. The application
of a VEGFR-3 fusion protein (called VEGF-C/D trap) was
able to inhibit the growth of tumour-associated lymphatic
vessels and inhibited tumour metastasis [162]. On the other
hand, administration of VEGF-C seems to have therapeutic
potential for patients with lymphedema since lymphatic
function ameliorated significantly [163]. However, the reg-
ulation of lymphatic vessel growth is more difficult because
it is not only promoted by the VEGF-C, VEGF-D/VEGFR-3
system. Several other growth factors and molecules that are
specific for lymphangiogenesis, of which the exact function
has not been resolved yet, could play an important role. An
efficient anti-lymphangiogenic therapy should target differ-
ent lymphatic growth factors. Furthermore, additional
information is needed on specific tumour lymphatic
markers. A recent paper of Zhang et al. presented some
promising results. In search for a lymphatic tissue specific
signature, it was demonstrated that tumour development is
associated with organ- and stage-specific changes in
lymphatics [164]. Although clinical implementation will
take years, cancer patients will benefit from anti-metastatic
therapy that can decrease metastatic lymphatic spread.
8 Conclusion
Tumours depend on the growth of a vascular network,
which is stimulated by a variety of angiogenic mediators,
providing them with blood and oxygen. Inhibition of
sprouting angiogenesis has gained a lot of progression.
Several clinical trials, in which specific growth factors or
receptors are being blocked, are currently being performed.
Strategies that block the VEGF-A/VEGFR2 signalling are
the most abundant ones in the field of anti-angiogenic the-
rapy. After successful clinical trials, Avastin is now entering
into the clinic. Because side effects are observed, the
emphasis of such growth factor inhibition mediated treat-
ment may shift towards other growth factors, e.g. PLGF
[17], or to simultaneous targeting of multiple pathways.
Clinical success of anti-angiogenesis therapy is present
but still limited. Since anti-angiogenic therapy alone seems
not to be sufficient to improve patient survival, clinical
studies are all in combination with conventional strategies,
such as chemo- and radiotherapy. The successful combina-
tion of chemotherapy and anti-angiogenesis therapy may
benefit from the normalization of the tumour vasculature by
anti-angiogenic therapy and subsequently a better adminis-
tration of chemotherapy [165].
It is clear now that tumour vasculature is not necessarily
dependent of endothelial cell proliferation and sprouting of
new capillaries. Several additional mechanisms can provide
the tumour of oxygen and nutrients. The molecular players
involved and their specific role in tumour development still
need to be elucidated. The current knowledge that anti-
angiogenesis therapy work best in combination with che-
motherapy, should probably in the near future be extended
to other types of vascularization as well. There is still a long
way to go before we fully understand the different mech-
Cancer Metastasis Rev (2007) 26:489–502 497anisms of tumor vascularization. But we anticipate that
combination of a multimodal anti-vascular approach, repre-
senting anti-angiogenesis, anti-lymphangiogenesis and vascu-
logenic mimicry targeting, together with chemotherapy may
become the best possible strategy in the fight against cancer.
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